NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $3.00 -0.11 (-3.54%) Closing price 09/24/2026 04:00 PM EasternExtended Trading$2.96 -0.04 (-1.50%) As of 06:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About X4 Pharmaceuticals Stock (NASDAQ:XFOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get X4 Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.96▼$3.1050-Day Range$3.00▼$4.6452-Week Range$2.80▼$4.83Volume973,597 shsAverage Volume910,878 shsMarket Capitalization$297.45 millionP/E RatioN/ADividend YieldN/APrice Target$11.25Consensus RatingModerate Buy Company Overview X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by abnormalities in the immune system. The company’s research is centered on the CXCR4 pathway, which helps regulate the movement and distribution of immune cells in the body. X4’s lead product, XOLREMDI (mavorixafor), is an orally administered CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for patients aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency characterized by chronic neutropenia, low levels of other white blood cells, and increased susceptibility to infections. XOLREMDI is designed to increase circulating neutrophils and lymphocytes and is intended for long-term treatment of the condition. The company’s activities are primarily focused on the United States, where it is commercializing XOLREMDI while continuing to evaluate mavorixafor in additional rare-disease and immune-cell disorders. X4 Pharmaceuticals was founded as a biotechnology company developing CXCR4-targeted medicines and became a publicly traded company on the Nasdaq exchange in 2019.AI Generated. May Contain Errors. Read More X4 Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreXFOR MarketRank™: X4 Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 633rd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingX4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialX4 Pharmaceuticals has a consensus price target of $11.25, representing about 275.0% upside from its current price of $3.00.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for X4 Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about X4 Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.40% of the float of X4 Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 7.07.Change versus previous monthShort interest in X4 Pharmaceuticals has recently increased by 14.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentX4 Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for XFOR on MarketBeat in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $356,126.00 in company stock.Percentage Held by Insiders1.13% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XFOR Stock News HeadlinesX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 18, 2026 | americanbankingnews.comX4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare ConferenceSeptember 9, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 25 at 1:00 AM | Porter & Company (Ad)X4 Pharmaceuticals Announces Positive Outcome From FDA Type C Meeting And Provides Update On 4WARD Phase 3 Chronic Neutropenia TrialSeptember 8, 2026 | marketscreener.comMX4 Pharmaceuticals Announces Positive Outcome from FDA Type C MeetingSeptember 8, 2026 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 1, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) Receives a Buy from Stifel NicolausAugust 9, 2026 | theglobeandmail.comX4 Pharmaceuticals: Q2 Earnings SnapshotAugust 6, 2026 | chron.comSee More Headlines XFOR Stock Analysis - Frequently Asked Questions How have XFOR shares performed this year? X4 Pharmaceuticals' stock was trading at $4.00 at the beginning of the year. Since then, XFOR shares have decreased by 25.0% and is now trading at $3.00. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. The business earned $8.81 million during the quarter, compared to analysts' expectations of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative trailing twelve-month return on equity of 63.05%. When did X4 Pharmaceuticals' stock split? X4 Pharmaceuticals's stock reverse split on the morning of Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did X4 Pharmaceuticals IPO? X4 Pharmaceuticals (XFOR) raised $40 million in an initial public offering on Thursday, November 16th 2017. The company issued 4,000,000 shares at $10.00 per share. Who are X4 Pharmaceuticals' major shareholders? Top institutional investors of X4 Pharmaceuticals include Braidwell LP (2.95%), Bank of New York Mellon Corp (0.21%), Squarepoint Ops LLC (0.07%) and Wellington Management Group LLP (0.05%). Insiders that own company stock include Adam R Craig, John Volpone, David Kirske, Paula Ragan, Mark Baldry, Mary Dibiase, Arthur Taveras and Adam S Mostafa. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Intel (INTC). Company Calendar Last Earnings8/06/2026Today9/25/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 XFOR's financial health is in the Green zone, according to TradeSmith. XFOR has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XFOR CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees45Year Founded2010Price Target and Rating Average Price Target for X4 Pharmaceuticals$11.25 High Price Target$12.00 Low Price Target$10.00 Potential Upside/Downside+275.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.20 million Net Margins-568.80% Pretax Margin-568.98% Return on Equity-63.05% Return on Assets-36.89% Debt Debt-to-Equity Ratio0.49 Current Ratio11.30 Quick Ratio11.02 Sales & Book Value Annual Sales$35.11 million Price / Sales8.47 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book1.41Miscellaneous Outstanding Shares99,150,000Free Float98,027,000Market Cap$297.45 million OptionableNo Data Beta0.39 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:XFOR) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XFOR Stock Alerts